Alzheimer's disease (AD) along with dementia is one of the largest unmet healthcare challenges of our time.
The socioeconomic costs of AD are enormous
More than 1% of the annual global value creation is spent on nursing our old and demented. According to recent estimates by Alzheimer's Disease International, more than 80% of all individuals living in nursing homes have dementia, and the number of demented persons requiring nursing will triple by 2050.
There is a huge unmet medical need for novel interventions to treat Alzheimer's disease and dementia.
Our understanding of the disease biology is rapidly evolving
Two classical hallmarks of pathology are found in the brains of patients with AD; the amyloid plaque and tangles of tau protein. Despite intense efforts to discover and develop novel drugs for AD targeting the amyloid plaque pathway, only one new symptomatic drug has been introduced on the market in the last ten years. Our current understanding of the disease biology has evolved rapidly in the past decades; we now see the role of tau protein, not as secondary to the plaques, but entering centre-stage as an important and necessary pathological factor alongside the amyloid plaques.
Pharmasum is developing novel drugs to treat dementia, targeting pathological tau protein.